Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tnbc, do you know of a round table about antibiotics in animals? My friend doesn't.
This might be the best explanation so far.
I agree. The explanation sounds plausible. But there was no such session planned and the organizers did not know where Dr. Menon was at he time of his planned presentation. I'm not trying to dig up dirt but this is something that simply doesn't add up.
And why were the organizers worried that something might had happened to Dr. Menon since he didn't show up if they themselves asked him to speak about something else than what was planned ?
Please see post #126643 by tnbc2012
There was only one session at a time. All the delegates and speakers were gathered in the conference room. My friend counted around 50-60 during the session about clinical development. The moderator announced that they were missing one speaker.
I'm baffled. There was no such planned session about animal feeding of antibiotics and there was only one session at a time. I got that confirmed.
How did you come up with this 100 % inaccurate (false) story ?
CLINICAL DEVELOPMENT 10.40 Changing the clinical landscape: using smart diagnostics and out of the box thinking to achieve clinical success ? Danger of spurring incentives with invalid clinical methods ? Using diagnostics to select patient subsets for specifically designed trials ? The importance of non-inferiority studies for antimicrobial development John Powers, Associate Professor of Clinical Medicine, George Washington University 11.00 Update on Brilacidin development for bacterial skin infections ? Building a patient population for your clinical trials ? Developing a stable manufacturing process for clinical and commercial scale expansion ? Transition between in-house and contract labs for clinical work Krishna Menon, Chief Scientific Officer, Cellceutix 11.20 Adapting to clinical changes and shifting FDA guidelines for development of Avycaz ? First approved FDA drug after new guidelines – reacting to changes to the phase III trial progression ? Tackling an unmet need and setting an anti-infective apart through efficacy and targeting
Yes. Shoot me a pm with your email address and I will mail it to you. I don't have PM.
From the agenda that was handed out today he was going to talk about B
Yeah. Same story from my friend who was there. The moderator announced at the beginning that one speaker wasn't there and that they would have more time for questions. The 3 other speakers just got some more time.
On a positive note I was told that the conference was by invitation only. So this highly specialized and professional crowd wanted to hear about Brilacidin as one out of only 4 presentation about clinical development. That's significant. Menon not showing up probably isn't a big thing. But being invited is. I only reported the facts about the no show because I was awaiting news about the presentation that didn't happen - no FUD here.
Menon didn't show up for his presentation. Was he there ? Maybe. But he didn't speak. Why ? I don't know. Is it a big deal ? Probably not.
If you don't believe me and my source call Terrapin for confirmation ?
He might have the flu. It's that season. And he's only human.
That it would NOT have brought a lot of media attention. Sorry. On phone.
If true - what are you implying ?
I do agree though that it would have brought lots of media attention. My friend says that roughly 50 people were present and no media at all. Only professionals.
I have a friend who attends the conference in DC. He just wrote me that Dr. Menon never showed up and that the 3 other speakers got some extra time. No explanation given.
I like everything about this summary. Apart from the photo. Who wants to contribute to a gift card for new head shots ? Both Leo and Dr. Menon could use it.
Dr. Menon - Bio / CTIX info
This is the bio and info listed on the DC AMR conference website.
http://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/speaker-krishna-MENON.stm
Dr Krishna Menon | Chief Scientific Officer
Cellceutix CORP
Dr Krishna Menon, Chief Scientific Officer, Cellceutix CORP
After graduating with a PhD in Pharmacology from Kerala University and with a Doctorate in Veterinary Medicine, Dr. Menon began his career as Chief Government Veterinarian for a major Parish in Jamaica from 1976 to 1981. He later served as Director of Agriculture for Cayman Islands from 1981 to 1983. Dr. Menon migrated to Boston, Massachusetts where he worked, amongst other endeavors, as a Research Scientist at Dana Farber Cancer Institute under Dr. Emil Frei III and taught Veterinary Sciences at Tufts University. He later moved to Connecticut to take a position as Senior Research Scientist, In Vivo Research at Bayer Pharmaceuticals (Miles Laboratories).
Again relocating to Indianapolis, Indiana Dr. Menon became Group Leader for In Vivo Research and Clinical Development, at Eli Lilly and Company. While at Lilly, Dr. Menon Worked on two drugs GEMZAR and ALIMTA that became blockbusters hits and known worldwide. He was also awarded the Employee of the Year, President Award (1999) due to his numerous achievements. After his success at Lilly, Dr. Menon returned to Massachusetts and accepted the position as Director of Operations for the ALS Therapy Development Foundation from 2001 to 2002.
With over 20 years of experience and great career success Dr. Menon made the decision to start his own company where he could focus his many years of industry knowledge and scientific expertise. In 2002, Dr. Menon founded KARD Scientific, a contract research organization, specializing in pre-clinical drug development. He worked and scientific developments through KARD let him to co-found Cellceutix in 2007, where he currently serves as President, Director, and Chief Scientific Officer.
Dr. Menon gained numerous accolades through is 30+ years of work in the pharmaceutical field. In his past endeavors Dr. Menon has worked on countless drugs. Currently at Cellceutix, Dr. Menon is steadily working on various technologies that work toward the goal of developing innovative small molecule therapies for areas of unmet medical need, particularly infectious disease, oncology and dermatology. Dr. Menon is now focusing on 3 drugs in particular, Kevetrin, Brilacidin, and Prurisol all of them are in clinical stages, and targets specifically resistant strains.
The major drug currently in clinical trials for Cellceutix is Brilacidin. Licensed from the University of Pennsylvania, Brilacidin is the first of a completely new class of antibiotics called defensin-mimetics. Brilacidin kills bacteria in the same manner as the human immune system, and in this regard, can significantly reduce the risk of bacterial resistance.
Dr. Menon’s focus is on finding new and better methods to treat diseases that are debilitating to the world and have unmet pharmaceutical needs. The current work is still progressing with new compounds developed by his lab for gram positive and negative bacteria and an active anti-fungal program that also tackles resistant strains. New INDs are planned for these programs in the 2016.
- See more at: http://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/speaker-krishna-MENON.stm#sthash.GIBJ38nP.dpuf
Will anyone here be attending the conference in DC next week ?
This is a great post. My thoughts exactly.
http://www.asx.com.au/asxpdf/20151007/pdf/431wrycb3wmz7z.pdf
Lagoda accumulating heavily. Now over 6%.
This is good news. We now know that Clinuvel is more or less certain to gain FDA approval for EPP on accelerated approval. Only question is when they will be ready (requested) to submit the dossier.
True !
Do you know the shelf life of B ? A lot of work has to be going on in order to use such a significant amount of B.
Sun corrected me. I missed a significant number of decimals. It's 150.000 doses.
Of course. I knew I shouldn't have put whiskey in my coffee this am. So that's roughly 150.000 doses of B. That's... a lot.
Help me out here.
If we take the 1.2 mg per kilo dose and assumes that an average person is 80 kg then a single dose B equals 96 mg.
30 pounds is roughly 15 kg. 15 kg is 15.000 mg.
15.000 / 96 = 156 doses.
Is this correct ? What am I missing?
But take a look at the trading pattern down under last night. Lots of 5000 shares chunks sold and then at the end two small parcels sold to wack down the pps.
Sorry. 13F is due 45 days after the end of quarter. So we'll have to wait till November 14th if they don't file early.
No. I don't think PW has orchestrated this. I think an investor who has the intention of keeping a lid on the pps while accumulating could have done it.
TOP 10 SHAREHOLDERS:
FIL Investment Management (Hong Kong) Ltd. 2,662,583 5.98%
Ender 1 LLC (SEAN PARKER) 2,340,824 5.25%
Lagoda Investment Management LP 2,160,713 4.85%
Philippe J. Wolgen MD, MBA 2,079,832 4.67%
Mark Edwin Badcock 1,070,200 2.40%
FIL Investment Management (Singapore) Ltd. 451,928 1.01%
Headstart Global Aggressive Holdings Ltd. 379,515 0.85%
Mark William Iliff 351,074 0.79%
Headstart Global Holdings Ltd. 337,633 0.76%
Biotech Lab Singapore Pte Ltd. 301,568 0.68%
Has anyone on this board had the opportunity to discuss this with the CEO ? Does he recognize that staying pink was a mistake ? What is his view on all this ?
Please don't fell you have to excuse anything. Your research is very much appreciated.
Look out for the 13F by Lagoda due tomorrow. It will show how much they have accumulated since the filing of the Aussie Form 603 - becoming a significant shareholder (+5%).
I believe that Lagoda intentionally did not buy the last 1 million shares chunk but that someone else did and hat this entity is now selling those shares to Lagoda who can accumulate without driving the pps up. 13F will might reveal if I'm right.
Likewise. Someday in the not so distant future we will have many new people coming to this board. Good luck. I hope you will make a good profit.
It seems so. Mr. Zagami who is now lead plantiff in the case against CTIX was also lead plaintiff in a case that Rosen Law had in 2009. A lenghty case that ended in a settlement.
Rosen lists this particular case as one of their successes:
Zagami v. Natural Health Trends Corp., et al., Case No. 3:06-CV-1654-D
The Rosen Law Firm served as sole Lead Counsel in this class action in the U.S. District Court for the Northern District of Texas. The complaint alleged violations of § 10b and 20(a) of the Securities Exchange Act arising out of the Company’s issuance of materially false and misleading financial statements in violation of GAAP. Plaintiffs settled this case for $2.75 million cash payment to class members.
So Ms. O'Connell bought a staggering amount of shares it seems. 300. I see why she wanted to sue CTIX. What a joke.
Leo has never lied. He has exaggerated in some of his PR's. But everything he has mentioned so far has come to fruition eventually.
Not to rain on the parade but official minutes from any FDA meeting are to be expected within 60 days from the occurrence of the meeting.
As of 06/30 Lagoda had 36 positions.
http://www.nasdaq.com/quotes/institutional-portfolio/lagoda-investment-management-lp-956088
Clinuvel now represents app. the same value in their portfolio as Berkshire Hathaway and Valeant.
Lagoda does not usually invest in risky small caps it seems. So they must be pretty confident that Clinuvel will be a multi-bagger or they wouldn't invest.
Also, they kept buying after they acquired Retrophin's lot so I assume they are still accumulating.